Biotechnology Stocks Under Investors' Scanner -- Mast Therapeutics, ZIOPHARM Oncology, Amicus Therapeutics, and Repros Therapeutics

Jul 26, 2016, 08:30 ET from Chelmsford Park SA

NEW YORK, July 26, 2016 /PRNewswire/ --

Biotech firms have been battling with clinical-trial costs, pricing issues, tight policies, and economic slowdowns. However, investors and analysts remain optimistic as M&A activities continue to drive industry growth, presenting buying opportunities and reasonable dividend yields. evaluates these equities today: Mast Therapeutics Inc. (NYSE MKT: MSTX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Repros Therapeutics Inc. (NASDAQ: RPRX). Learn more about these stocks by accessing their freenotes at:

Mast Therapeutics 

San Diego, California headquartered Mast Therapeutics Inc.'s stock finished Monday's session 4.59% lower at $0.42. A total volume of 3.58 million shares was traded, which was above their three months average volume of 2.91 million shares. The Company's shares have surged 31.19% in the previous three months. The stock is trading 3.91% and 10.96% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have a Relative Strength Index (RSI) of 47.00.

As per the July 25th, 2016 dated notes filed with the SEC on July 22nd, 2016, Mast Therapeutics entered into an amendment to the Loan and Security Agreement, dated August 11th, 2015, with Hercules Technology III, L.P. and Hercules Capital, Inc. The Loan Agreement provides for a $15 million debt facility, $5 million of which was funded Mast Therapeutics in August 2015 and $10 million of which was funded to the Company in September 2015. As of July 25th, 2016, the principal balance of the loan was approximately $14.6 million.Under the Loan Agreement, on or before October 14th, 2016, the Company must demonstrate, positive results from its Phase 3 clinical study of vepoloxamer in patients with sickle cell disease, or prepay to Hercules $10 million of the principal balance of the loan and any accrued but unpaid fees and expenses (the "Second Advance Prepayment"), without any prepayment penalty. In the event that the Second Advance Prepayment Condition is not satisfied, the Second Advance Prepayment would be due on October 14, 2016. MSTX complete notes are just a click away at:

ZIOPHARM Oncology 

On Monday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. recorded a trading volume of 1.55 million shares and ended the session 3.79% higher at $4.66. The stock is trading 25.87% below its 50-day moving average. Shares of the Company have an RSI of 32.85.

On July 19th, 2016, ZIOPHARM Oncology provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant glioma. The patient death resulting from intracranial hemorrhage in the third cohort of this Phase I study was deemed unrelated to study drug following the receipt and analysis of additional information by the sponsor and the study's Safety Review Committee.

On July 19th, 2016, research firm Mizuho reiterated its 'Neutral' rating with a decrease of the target price to $5 a share from $7 a share for the Company's stock.The complimentary notes on ZIOPcan be accessed at:

Amicus Therapeutics 

Shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. closed the day flat at $6.00 with a total volume of 884,694 shares traded. The stock has gained 1.52% in the last month. The Company's shares are trading 4.34% below their 50-day moving average. Additionally, shares of Amicus Therapeutics, which focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases, have an RSI of 49.59.

On July 07th, 2016, Amicus Therapeutics, announced that it has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 deficiency, a rare and devastating genetic neurological disease for which there is no currently approved treatment. Sign up for your complimentary notes on FOLD at:

Repros Therapeutics 

At the close, shares in The Woodlands, Texas-based Repros Therapeutics Inc. ended at $1.68, dropping 5.08%. The stock recorded a trading volume of 146,821 shares. The Company's shares have advanced 38.84% on an YTD basis and are trading below their 50-day moving average by 6.83%. Furthermore, shares of Repros Therapeutics, which focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the U.S., have an RSI of 47.11.

As per the notes filed with SEC on June 28th, at the 2016 Annual Meeting of Stockholders of Repros Therapeutics Inc., the stockholders of the Company voted on the election of six directors, the ratification and approval of the appointment of PricewaterhouseCoopers LLP as the Company's registered independent public accounting firm for the fiscal year ending December 31, 2016, and an advisory vote to approve, on an advisory basis, the compensation of the Company's named executive officers. Get free access to your notes on RPRX at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email RohitTuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA